...
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Reduction of unnecessary antibiotic therapy in newborn infants using interleukin-8 and C-reactive protein as markers of bacterial infections.
【24h】

Reduction of unnecessary antibiotic therapy in newborn infants using interleukin-8 and C-reactive protein as markers of bacterial infections.

机译:使用白介素8和C反应蛋白作为细菌感染的标志物,减少新生婴儿不必要的抗生素治疗。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: To examine whether the determination of interleukin 8 (IL-8) and C-reactive protein (CRP) in neonates with suspected nosocomial bacterial infection (NBI) is feasible and cost-effective in reducing antibiotic therapy. METHODS: Between April 1996 and May 1997, IL-8 was measured 260 times along with blood cultures, CRP, and immature-to-total-neutrophil (IT) ratio for suspected NBI in term and preterm neonates. All infants were retrospectively analyzed for NBI. Sensitivity, specificity, positive and negative predictive values, and 95% confidence intervals were calculated for IL-8, CRP, and IT ratio. Receiver-operating characteristic curves were analyzed to determine optimal thresholds. Between June 1997 and June 1998, IL-8 was measured 215 times in newborn infants with suspected NBI and the decision to start antibiotic therapy was based on increased IL-8 and/or CRP values. A cost-effectiveness analysis was performed and sensitivity, specificity, and receiver-operating characteristic curves were reevaluated. RESULTS: At the first suspicion of NBI, the combination of IL-8 >/= 53 pg/mL and/or CRP >10 mg/L detected culture-proven NBI with 96% sensitivity. The combined culture-proven and clinical NBI were detected with 93% sensitivity and 80% specificity. The use of IL-8 reduced unnecessary antibiotic therapy for suspected NBI by 73% and was cost-effective when compared with initiating antibiotic therapy based on clinical signs alone or based on clinical signs and an increased IT ratio and/or CRP. CONCLUSIONS: The combination of IL-8 and/or CRP is a reliable and early test for the diagnosis of NBI in newborn infants. Using the combination of IL-8 and/or CRP to restrict antibiotic therapy to truly infected infants reduces unnecessary antibiotic therapy and is cost-effective.
机译:目的:探讨在怀疑有医院内细菌感染(NBI)的新生儿中测定白细胞介素8(IL-8)和C反应蛋白(CRP)是否可行且具有成本效益,以减少抗生素治疗。方法:在1996年4月至1997年5月期间,对足月和早产儿可疑NBI进行了260次IL-8测定,并进行了血液培养,CRP和未成熟的总中性粒细胞(IT)比率。回顾性分析所有婴儿的NBI。计算IL-8,CRP和IT比的敏感性,特异性,阳性和阴性预测值以及95%置信区间。分析接收器工作特性曲线以确定最佳阈值。在1997年6月至1998年6月之间,对怀疑患有NBI的新生儿进行了IL-8测定,测定了215次,而开始抗生素治疗的决定是基于IL-8和/或CRP值升高。进行了成本效益分析,并重新评估了敏感性,特异性和受体操作特性曲线。结果:在首次怀疑NBI时,IL-8> / = 53 pg / mL和/或CRP> 10 mg / L的组合检测到经培养证明的NBI,敏感性为96%。结合培养物验证和临床NBI的检测灵敏度为93%,特异性为80%。与仅基于临床体征或基于临床体征和增加IT比率和/或CRP进行抗生素治疗相比,使用IL-8减少了可疑NBI不必要的抗生素治疗73%,并且具有成本效益。结论:IL-8和/或CRP的组合是诊断新生儿NBI的可靠且早期的测试。使用IL-8和/或CRP的组合将抗生素治疗限于真正感染的婴儿,可以减少不必要的抗生素治疗,并且具有成本效益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号